Obstetrics and Gynaecology - Research Publications

Permanent URI for this collection

Search Results

Now showing 1 - 3 of 3
  • Item
    Thumbnail Image
    The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for children at 18 months
    Duley, L ; Farrell, B ; Armstrong, N ; Spark, P ; Roberts, B ; Smyth, R ; Tivnan, M ; Laws, A ; Corfield, N ; Salter, A ; Thorn, L ; Altman, D ; Yu, L-M ; Abalos, E ; Carroli, B ; Dellepiane, L ; Duarte, M ; Fernandez, H ; Giordano, D ; Altman, D ; Armstrong, N ; Clarke, M ; Duley, L ; Farrell, B ; Gray, A ; Hey, E ; Neilson, J ; Simon, J ; Spark, P ; Smyth, R ; Yu, L-M ; Doyle, L ; Hey, E ; Kelly, T ; Squires, J ; Altman, D ; Collins, R ; Duley, L ; Farrell, B ; Karaoglou, A ; Lilford, R ; Moodley, J ; Neilson, J ; Robson, S ; Roberts, I ; Rubin, P ; Thornton, J ; Twaddle, S ; Villar, J ; Walker, I ; Watkins, C ; Abalos, E ; Altman, D ; Armstrong, N ; Doyle, L ; Duley, L ; Farrell, B ; Hey, E ; Moodley, J ; Neilson, J ; Spark, P ; Smyth, R ; Yu, L-M ; Bimbashi, A ; Demalia, E ; Gliozheni, O ; Shpata, A ; Karolinski, A ; Lamas, M ; Pesaresi, M ; Wainer, V ; Barbato, W ; Paciocco, M ; Bertin, M ; Boiza, E ; Castaldi, J ; Partida, Y ; Farri, M ; Kerz, G ; Aguirre, J ; de Sagastiza, M ; Falcone, R ; Morales, E ; Carroli, G ; Krupitzky, S ; Lopez, S ; Palermo, M ; Varela, DM ; Delprato, H ; Camusso, H ; Curioni, M ; Ludmer, E ; Brandi, R ; Martin, R ; Mesas, W ; Taralli, R ; Lezaola, M ; Morosini, M ; Andina, E ; Bernal, L ; Estiu, M ; Ulens, E ; de Speranza, BO ; Peyrano, A ; Damiano, M ; Saumench, C ; Horn, J ; Pritchard, M ; Smith-Orr, V ; Wilson, M ; Lawrence, A ; Watson, D ; Crowther, C ; Paynter, J ; Mannan, M ; Shahidullah, M ; Shamsuddin, L ; Barros Santos, C ; Freire, S ; Melo, E ; Cobo, E ; Jaramillo, M ; Cardozo, C ; Fandino, N ; Gaitan, H ; Montano, L ; Lozano, J ; Rojas, M ; Breto Garcia, A ; Fuentes Ramirez, A ; Garcia Miras, R ; Sampera, S ; Farnot, U ; Gomez, E ; Rojas, G ; Valdez, R ; El-Kreem, HA ; Al-Hussaini, T ; Hammad, E ; Danso, K ; Kwapong, E ; Ofosu-Barko, F ; Jasper, MP ; Peedicayil, A ; Regi, A ; Sharma, R ; Chauhan, A ; Raut, V ; Udani, R ; Batra, S ; Muthal-Rathore, A ; Ramji, S ; Zutshi, V ; Balakrishnan, S ; Eapen, E ; Koshy, G ; Ambardar, B ; Vadakkepat, P ; Vaidya, D ; Lema, V ; Rijken, Y ; Tadesse, E ; Dada, O ; Sofekun, A ; Ohiaeri, C ; Runsewe-Abiodun, T ; Adewole, I ; Adeyemo, A ; Brown, B ; Oladokun, R ; Adewale, O ; Inimgba, N ; John, C ; Ogu, R ; Ekele, B ; Isah, A ; Onankpa, B ; Jamelle, R ; Junejo, D ; Faiz, NR ; Gul, F ; Sherin, A ; Bangash, K ; Mahmud, G ; Masud, K ; Tasneem, N ; Gassama, S ; Soyei, A ; Agarwal, P ; Rajadurai, V ; Hani, C ; Pirani, N ; Delport, S ; Macdonald, P ; Mokhondo, R ; Pattinson, R ; Zondo, M ; Adhikari, M ; Mnguni, N ; Moodley, J ; Carstens, M ; Kirsten, G ; Steyn, W ; van Zyl, J ; Helwig, A ; Jacobson, S-L ; Panosche, R ; Hammond, E ; Masanganise, L (WILEY, 2007-03-01)
    OBJECTIVE: To assess the long-term effects of in utero exposure to magnesium sulphate for children whose mothers had pre-eclampsia. DESIGN: Assessment at 18 months of age for children whose mothers were recruited to the Magpie Trial (recruitment 1998-2001 ISRCTN 86938761), which compared magnesium sulphate with placebo. SETTING: Follow-up of children born at 125 centres in 19 countries across five continents. POPULATION: A total of 6922 children were born to women randomised before delivery at follow-up centres. Of these, 2271 were not included for logistic reasons and 168 were excluded (101 at a centre where <20% were contacted, 40 whose death or disability was due to a problem at conception or embryogenesis and 27 whose parent/s opted out). Therefore, 4483 children were included in follow-up, of whom 3283 (73%) were contacted. METHODS: Assessment by questionnaire, with interview and neurodevelopmental testing of selected children. MAIN OUTCOME MEASURES: Death or neurosensory disability at age of 18 months. RESULTS: Of those allocated magnesium sulphate, 245/1635 (15.0%) were dead or had neurosensory disability at 18 months compared with 233/1648 (14.1%) allocated placebo (relative risk [RR] 1.06, 95% CI 0.90-1.25), and of survivors, 19/1409 (1.3%) had neurosensory disability at 18 months compared with 27/1442 (1.9%) (RR 0.72, 95% CI 0.40-1.29). There were no substantial differences in causes of death or in the risk of individual impairments or disabilities. CONCLUSIONS: The lower risk of eclampsia following prophylaxis with magnesium sulphate was not associated with a clear difference in the risk of death or disability for children at 18 months.
  • Item
    Thumbnail Image
    The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for women at 2 years
    Duley, L ; Farrell, B ; Armstrong, N ; Spark, P ; Roberts, B ; Smyth, R ; Tivnan, M ; Laws, A ; Corfield, N ; Salter, A ; Thorn, L ; Altman, D ; Yu, L-M ; Abalos, E ; Carroli, B ; Dellepiane, L ; Duarte, M ; Fernandez, H ; Giordano, D ; Clarke, M ; Gray, A ; Hey, E ; Neilson, J ; Simon, J ; Collins, R ; Karaoglou, A ; Lilford, R ; Moodley, J ; Robson, S ; Roberts, I ; Rubin, P ; Thornton, J ; Twaddle, S ; Villar, J ; Walker, I ; Watkins, C ; Doyle, L ; Bimbashi, A ; Demalia, E ; Gliozheni, O ; Shpata, A ; Karolinski, A ; Lamas, M ; Pesaresi, M ; Wainer, V ; Barbato, W ; Paciocco, M ; Bertin, M ; Boiza, E ; Castaldi, J ; Partida, Y ; Arias, C ; Farri, M ; Kerz, G ; Aguirre, J ; de Sagastizabal, M ; Falcone, R ; Morales, E ; Carroli, G ; Krupitzky, S ; Lopez, S ; Palermo, M ; Varela, DM ; Delprato, H ; Camusso, H ; Curioni, M ; Ludmer, E ; Brandi, R ; Martin, R ; Mesas, W ; Taralli, R ; Lezaola, M ; Morosini, M ; Andina, E ; Bernal, L ; Estiu, M ; Ulens, E ; de Speranza, BO ; Peyrano, A ; Damiano, M ; Saumench, C ; Horn, J ; Pritchard, M ; Smith-Orr, V ; Wilson, M ; Lawrence, A ; Watson, D ; Crowther, C ; Paynter, J ; Ashrafunnessa, ; Mannan, M ; Shahidullah, M ; Shamsuddin, L ; Santos, CB ; Freire, S ; Melo, E ; Cobo, E ; Jaramillo, M ; Cardozo, C ; Fandino, N ; Gaitan, H ; Montano, L ; Lozano, J ; Rojas, M ; Garcia, AB ; Ramirez, AF ; Miras, RG ; Sampera, S ; Farnot, U ; Gomez, E ; Rojas, G ; Valdes, R ; El-Kreem, HA ; Al-Hussaini, T ; Hammad, E ; Danso, K ; Kwapong, E ; Ofosu-Barko, F ; Jasper, MP ; Peedicayil, A ; Regi, A ; Sharma, R ; Chauhan, A ; Raut, V ; Udani, R ; Batra, S ; Muthal-Rathore, A ; Ramji, S ; Zutshi, V ; Balakrishnan, S ; Eapen, E ; Koshy, G ; Ambardar, B ; Vadakkepat, P ; Vaidya, D ; Lema, V ; Rijken, Y ; Tadesse, E ; Dada, O ; Sofekun, A ; Ohiaeri, C ; Runsewe-Abiodun, T ; Adewole, I ; Adeyemo, A ; Brown, B ; Oladokun, R ; Adewale, O ; Inimgba, N ; John, C ; Ogu, R ; Ekele, B ; Isah, A ; Onankpa, B ; Jamelle, R ; Junejo, D ; Faiz, N ; Gul, F ; Sherin, A ; Bangash, K ; Mahmud, G ; Masud, K ; Tasneem, N ; Gassama, S ; Soyei, A ; Agarwal, P ; Rajadurai, V ; Pirani, N ; Delport, S ; Macdonald, P ; Mokhondo, R ; Pattinson, R ; Zondo, M ; Adhikari, M ; Mnguni, N ; Moodley, J ; Carstens, M ; Kirsten, G ; Steyn, W ; van Zyl, J ; Helwig, A ; Jacobson, S-L ; Panosche, R ; Hammond, E ; Masanganise, L (WILEY, 2007-03-01)
    OBJECTIVE: The aim of this study was to assess long-term effects for women following the use of magnesium sulphate for pre-eclampsia. DESIGN: Assessment at 2-3 years after delivery for women recruited to the Magpie Trial (recruitment in 1998-2001, ISRCTN 86938761), which compared magnesium sulphate with placebo for pre-eclampsia. SETTING: Follow up after discharge from hospital at 125 centres in 19 countries across five continents. POPULATION: A total of 7927 women were randomised at the follow-up centres. Of these women, 2544 were not included for logistic reasons and 601 excluded (109 at a centre where <20% of women were contacted, 466 discharged without a surviving child and 26 opted out). Therefore, 4782 women were selected for follow-up, of whom 3375 (71%) were traced. METHODS: Questionnaire assessment was administered largely by post or in a dedicated clinic. Interview assessment of selected women was performed. Main outcome measures Death or serious morbidity potentially related to pre-eclampsia at follow up, other morbidity and use of health service resources. RESULTS: Median time from delivery to follow up was 26 months (interquartile range 19-36). Fifty-eight of 1650 (3.5%) women allocated magnesium sulphate died or had serious morbidity potentially related to pre-eclampsia compared with 72 of 1725 (4.2%) women allocated placebo (relative risk 0.84, 95% CI 0.60-1.18). CONCLUSIONS: The reduction in the risk of eclampsia following prophylaxis with magnesium sulphate was not associated with an excess of death or disability for the women after 2 years.
  • Item
    Thumbnail Image
    Improving the outcome of infants born at < 30 weeks' gestation - a randomized controlled trial of preventative care at home
    Spittle, AJ ; Ferretti, C ; Anderson, PJ ; Orton, J ; Eeles, A ; Bates, L ; Boyd, RN ; Inder, TE ; Doyle, LW (BMC, 2009-12-03)
    BACKGROUND: Early developmental interventions to prevent the high rate of neurodevelopmental problems in very preterm children, including cognitive, motor and behavioral impairments, are urgently needed. These interventions should be multi-faceted and include modules for caregivers given their high rates of mental health problems. METHODS/DESIGN: We have designed a randomized controlled trial to assess the effectiveness of a preventative care program delivered at home over the first 12 months of life for infants born very preterm (<30 weeks of gestational age) and their families, compared with standard medical follow-up. The aim of the program, delivered over nine sessions by a team comprising a physiotherapist and psychologist, is to improve infant development (cognitive, motor and language), behavioral regulation, caregiver-child interactions and caregiver mental health at 24 months' corrected age. The infants will be stratified by severity of brain white matter injury (assessed by magnetic resonance imaging) at term equivalent age, and then randomized. At 12 months' corrected age interim outcome measures will include motor development assessed using the Alberta Infant Motor Scale and the Neurological Sensory Motor Developmental Assessment. Caregivers will also complete a questionnaire at this time to obtain information on behavior, parenting, caregiver mental health, and social support. The primary outcomes are at 24 months' corrected age and include cognitive, motor and language development assessed with the Bayley Scales of Infant and Toddler Development (Bayley-III). Secondary outcomes at 24 months include caregiver-child interaction measured using an observational task, and infant behavior, parenting, caregiver mental health and social support measured via standardized parental questionnaires. DISCUSSION: This paper presents the background, study design and protocol for a randomized controlled trial in very preterm infants utilizing a preventative care program in the first year after discharge home designed to improve cognitive, motor and behavioral outcomes of very preterm children and caregiver mental health at two-years' corrected age. CLINICAL TRIAL REGISTRATION NUMBER: ACTRN12605000492651.